Vaccines for established cancer: overcoming the challenges posed by immune evasion

Area of Science:

• Oncology
• Immunology
• Vaccinology

Background:

• Therapeutic vaccines stimulate T cells against tumor-specific targets.
• Monotherapy is effective in early-stage cancers (e.g., carcinoma in situ, minimal residual disease).
• Established cancers necessitate combination therapies due to immune evasion.

Purpose of the Study:

• To review progress in overcoming tumor immune evasion.
• To summarize strategies for maximizing therapeutic benefit in established cancers.
• To discuss enhancing vaccine design and combination approaches.

Main Methods:

• Review of current research on therapeutic cancer vaccines.
• Analysis of strategies to overcome tumor cell-intrinsic and microenvironment-mediated immune evasion.
• Synthesis of approaches combining vaccines with other therapies.

Main Results:

• Therapeutic vaccines can be effective as monotherapy in early disease stages.
• Combination treatments are crucial for efficacy in established cancers.
• Strategies include improving vaccine design and integrating vaccines with chemotherapy, checkpoint blockade, and adoptive T cell transfer.

Conclusions:

• Overcoming immune evasion is key to enhancing therapeutic vaccine efficacy.
• Combination strategies are essential for treating established cancers with vaccines.
• Future directions involve optimizing vaccine design and synergistic combinations to sustain anti-tumor T cell responses.